Celyad Oncology: Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
Regulatory News:
Celyad Oncology (Euronext: CYAD) (the “Company” or “Celyad Oncology”), today announces the below information following the issuance, on July 16, 2026, of 2,500,000 new shares of Celyad Oncology to an affiliate of Fortress Investment Group. As a result, the Company’s share capital has been increased to 10,437,000.00 EUR and is represented by 47,261,905 shares.
This information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the disclosure of major participations in issuers whose shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Figures – Modified on July 16, 2026, following the capital increase:
